display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
breast cancer - triple negative
camrelizumab plus SOC Li

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons